Serum stabilities of short tryptophan- and arginine-rich antimicrobial peptide analogs

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-8

  Nguyen, Leonard T ^a   Chau, Johnny K ^a   Perry, Nicole A ^a   de Boer, Leonie ^b   Zaat, Sebastian A J ^b   Vogel, Hans J ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; COMBI 1; COMBI 2; COMBI 3; COMBI 4; COMBI 5; COMBI 6; COMBI 7; LACTOFERRICIN; LACTOFERRICIN 1; LACTOFERRICIN 2; LACTOFERRICIN 3; LACTOFERRICIN 4; LACTOFERRICIN 5; LACTOFERRICIN 6; LACTOFERRICIN 7; LACTOFERRICIN 8; LACTOFERRICIN 9; POLYPEPTIDE ANTIBIOTIC AGENT; TRYPTOPHAN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE;

ACETYLATION; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACILLUS SUBTILIS; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYCLIZATION; ESCHERICHIA COLI; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROLYSIS; ISOTHERMAL TITRATION CALORIMETRY; MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN STABILITY; STAPHYLOCOCCUS AUREUS; BACTERIUM; BLOOD; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; STRUCTURE ACTIVITY RELATION;

BOVINAE;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; ARGININE; BACTERIA; HUMANS; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPTOPHAN;

EID: 77958581350     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012684     Document Type: Article

References (57)

1. Zasloff M (2002) Antimicrobial peptides of multicellular organisms. Nature 415: 389-395.
2. Hancock RE, Sahl HG (2006) Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 24: 1551-1557.
3. Chan DI, Prenner EJ, Vogel HJ (2006) Tryptophan- and arginine-rich antimicrobial peptides: structures and mechanisms of action. Biochim Biophys Acta 1758: 1184-1202.
4. Park Y, Hahm KS (2005) Antimicrobial peptides (AMPs): peptide structure and mode of action. J Biochem Mol Biol 38: 507-516.
5. Kovalchuk LV, Gankovskaya LV, Gankovskaya OA, Lavrov VF (2007) Herpes simplex virus: treatment with antimicrobial peptides. Adv Exp Med Biol 601: 369-376.
6. Boulanger N, Bulet P, Lowenberger C (2006) Antimicrobial peptides in the interactions between insects and flagellate parasites. Trends Parasitol 22: 262-268.
7. Meyer JE, Harder J (2007) Antimicrobial peptides in oral cancer. Curr Pharm Des 13: 3119-3130.
8. Gifford JL, Hunter HN, Vogel HJ (2005) Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell Mol Life Sci 62: 2588-2598.
9. Hunter HN, Jing W, Schibli DJ, Trinh T, Park IY, et al. (2005) The interactions of antimicrobial peptides derived from lysozyme with model membrane systems. Biochim Biophys Acta 1668: 175-189.
10. Hilpert K, Volkmer-Engert R, Walter T, Hancock RE (2005) High-throughput generation of small antibacterial peptides with improved activity. Nat Biotechnol 23: 1008-1012.
11. Haug BE, Stensen W, Kalaaji M, Rekdal O, Svendsen JS (2008) Synthetic antimicrobial peptidomimetics with therapeutic potential. J Med Chem 51: 4306-4314.
12. Raguse TL, Porter EA, Weisblum B, Gellman SH (2002) Structure-activity studies of 14-helical antimicrobial beta-peptides: probing the relationship between conformational stability and antimicrobial potency. J Am Chem Soc 124: 12774-12785.
13. Epand RM, Epand RF, Savage PB (2008) Ceragenins (cationic steroid compounds), a novel class of antimicrobial agents. Drug News Perspect 21: 307-311.
14. Nguyen LT, Schibli DJ, Vogel HJ (2005) Structural studies and model membrane interactions of two peptides derived from bovine lactoferricin. J Pept Sci 11: 379-389.
15. Rozek A, Powers JP, Friedrich CL, Hancock RE (2003) Structure-based design of an indolicidin peptide analogue with increased protease stability. Biochemistry 42: 14130-14138.
16. Unger T, Oren Z, Shai Y (2001) The effect of cyclization of magainin 2 and melittin analogues on structure, function, and model membrane interactions: implication to their mode of action. Biochemistry 40: 6388-6397.
17. Brewer D, Lajoie G (2002) Structure-based design of potent histatin analogues. Biochemistry 41: 5526-5536.
18. Appelt C, Wessolowski A, Soderhall JA, Dathe M, Schmieder P (2005) Structure of the antimicrobial, cationic hexapeptide cyclo(RRWWRF) and its analogues in solution and bound to detergent micelles. Chembiochem 6: 1654-1662.
19. Rosengren KJ, Goransson U, Otvos L, Jr., Craik DJ (2004) Cyclization of pyrrhocoricin retains structural elements crucial for the antimicrobial activity of the native peptide. Biopolymers 76: 446-458.
20. Dathe M, Nikolenko H, Klose J, Bienert M (2004) Cyclization increases the antimicrobial activity and selectivity of arginine- and tryptophan-containing hexapeptides. Biochemistry 43: 9140-9150.
21. Li P, Roller PP (2002) Cyclization strategies in peptide derived drug design. Curr Top Med Chem 2: 325-341.
22. Selsted ME (2004) Theta-defensins: cyclic antimicrobial peptides produced by binary ligation of truncated alpha-defensins. Curr Protein Pept Sci 5: 365-371.
23. Rosengren KJ, Clark RJ, Daly NL, Goransson U, Jones A, et al. (2003) Microcin J25 has a threaded sidechain-to-backbone ring structure and not a head-to-tail cyclized backbone. J Am Chem Soc 125: 12464-12474.
24. Jeu L, Fung HB (2004) Daptomycin: a cyclic lipopeptide antimicrobial agent. Clin Ther 26: 1728-1757.
25. Maisetta G, Di Luca M, Esin S, Florio W, Brancatisano FL, et al. (2008) Evaluation of the inhibitory effects of human serum components on bactericidal activity of human beta defensin 3. Peptides 29: 1-6.
26. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, et al. (1997) Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 88: 553-560.
27. Lee IH, Cho Y, Lehrer RI (1997) Effects of pH and salinity on the antimicrobial properties of clavanins. Infect Immun 65: 2898-2903.
28. Bowdish DM, Davidson DJ, Lau YE, Lee K, Scott MG, et al. (2005) Impact of LL-37 on anti-infective immunity. J Leukoc Biol 77: 451-459.
29. Lai JR, Huck BR, Weisblum B, Gellman SH (2002) Design of non-cysteinecontaining antimicrobial beta-hairpins: structure-activity relationship studies with linear protegrin-1 analogues. Biochemistry 41: 12835-12842.
30. Tam JP, Lu YA, Yang JL (2002) Correlations of cationic charges with salt sensitivity and microbial specificity of cystine-stabilized beta -strand antimicrobial peptides. J Biol Chem 277: 50450-50456.
31. Park IY, Cho JH, Kim KS, Kim YB, Kim MS, et al. (2004) Helix stability confers salt resistance upon helical antimicrobial peptides. J Biol Chem 279: 13896-13901.
32. Friedrich C, Scott MG, Karunaratne N, Yan H, Hancock RE (1999) Saltresistant alpha-helical cationic antimicrobial peptides. Antimicrob Agents Chemother 43: 1542-1548.
33. Svenson J, Brandsdal BO, Stensen W, Svendsen JS (2007) Albumin binding of short cationic antimicrobial micropeptides and its influence on the in vitro bactericidal effect. J Med Chem 50: 3334-3339.
34. Jang WS, Lee SC, Lee YS, Shin YP, Shin KH, et al. (2007) Antimicrobial effect of halocidin-derived peptide in a mouse model of Listeria infection. Antimicrob Agents Chemother 51: 4148-4156.
35. Deslouches B, Gonzalez IA, DeAlmeida D, Islam K, Steele C, et al. (2007) De novo-derived cationic antimicrobial peptide activity in a murine model of Pseudomonas aeruginosa bacteraemia. J Antimicrob Chemother 60: 669-672.
36. Noto PB, Abbadessa G, Cassone M, Mateo GD, Agelan A, et al. (2008) Alternative stabilities of a proline-rich antibacterial peptide in vitro and in vivo. Protein Sci 17: 1249-1255.
37. Kwakman PH, te Velde AA, Vandenbroucke-Grauls CM, van Deventer SJ, Zaat SA (2006) Treatment and prevention of Staphylococcus epidermidis experimental biomaterial-associated infection by bactericidal peptide 2. Antimicrob Agents Chemother 50: 3977-3983.
38. Huther A, Dietrich U (2007) The emergence of peptides as therapeutic drugs for the inhibition of HIV-1. AIDS Rev 9: 208-217.
39. Williams JA, Day M, Heavner JE (2008) Ziconotide: an update and review. Expert Opin Pharmacother 9: 1575-1583.
40. Tomita M, Takase M, Bellamy W, Shimamura S (1994) A review: the active peptide of lactoferrin. Acta Paediatr Jpn 36: 585-591.
41. Blondelle SE, Houghten RA (1996) Novel antimicrobial compounds identified using synthetic combinatorial library technology. Trends Biotechnol 14: 60-65.
42. Schibli DJ, Hwang PM, Vogel HJ (1999) The structure of the antimicrobial active center of lactoferricin B bound to sodium dodecyl sulfate micelles. FEBS Lett 446: 213-217.
43. Jing W, Hunter HN, Hagel J, Vogel HJ (2003) The structure of the antimicrobial peptide Ac-RRWWRF-NH2 bound to micelles and its interactions with phospholipid bilayers. J Pept Res 61: 219-229.
44. Junkes C, Wessolowski A, Farnaud S, Evans RW, Good L, et al. (2008) The interaction of arginine- and tryptophan-rich cyclic hexapeptides with Escherichia coli membranes. J Pept Sci 14: 535-543.
45. Rezansoff AJ, Hunter HN, Jing W, Park IY, Kim SC, et al. (2005) Interactions of the antimicrobial peptide Ac-FRWWHR-NH(2) with model membrane systems and bacterial cells. J Pept Res 65: 491-501.
46. Dos Santos Cabrera MP, Arcisio-Miranda M, Broggio Costa ST, Konno K, Ruggiero JR, et al. (2008) Study of the mechanism of action of anoplin, a helical antimicrobial decapeptide with ion channel-like activity, and the role of the amidated C-terminus. J Pept Sci 14: 661-669.
47. Shalev DE, Mor A, Kustanovich I (2002) Structural consequences of carboxyamidation of dermaseptin S3. Biochemistry 41: 7312-7317.
48. Matsuzaki K (1998) Magainins as paradigm for the mode of action of pore forming polypeptides. Biochim Biophys Acta 1376: 391-400.
49. Powell MF, Stewart T, Otvos L, Jr., Urge L, Gaeta FC, et al. (1993) Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum. Pharm Res 10: 1268-1273.
50. Park CB, Kim HS, Kim SC (1998) Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem Biophys Res Commun 244: 253-257.
51. Schibli DJ, Nguyen LT, Kernaghan SD, Rekdal O, Vogel HJ (2006) Structurefunction analysis of tritrpticin analogs: potential relationships between antimicrobial activities, model membrane interactions, and their micelle-bound NMR structures. Biophys J 91: 4413-4426.
52. Hoek KS, Milne JM, Grieve PA, Dionysius DA, Smith R (1997) Antibacterial activity in bovine lactoferrin-derived peptides. Antimicrob Agents Chemother 41: 54-59.
53. Richardson A, de Antueno R, Duncan R, Hoskin DW (2009) Intracellular delivery of bovine lactoferricin's antimicrobial core (RRWQWR) kills Tleukemia cells. Biochem Biophys Res Commun 388: 736-741.
54. Gill SC, von Hippel PH (1989) Calculation of protein extinction coefficients from amino acid sequence data. Anal Biochem 182: 319-326.
55. Cudic M, Condie BA, Weiner DJ, Lysenko ES, Xiang ZQ, et al. (2002) Development of novel antibacterial peptides that kill resistant isolates. Peptides 23: 2071-2083.
56. Krijgsveld J, Zaat SA, Meeldijk J, van Veelen PA, Fang G, et al. (2000) Thrombocidins, microbicidal proteins from human blood platelets, are Cterminal deletion products of CXC chemokines. J Biol Chem 275: 20374-20381.
57. Strom MB, Rekdal O, Svendsen JS (2002) Antimicrobial activity of short arginine- and tryptophan-rich peptides. J Pept Sci 8: 431-437.